In recent years, the detection of cell-free DNA (cfDNA) in blood has become increasingly important. This circulating cfDNA in the blood contains DNA fragments from both healthy cells and tumor cells. The analysis of this so-called “liquid biopsy” should make it possible to detect the development and progress of malignant processes early and with as little invasiveness as possible. In addition, miRNA, methylation and protein patterns in the blood can be detected from the liquid biopsy mould. In the future, it is conceivable that this form of liquid diagnostics will also be used for therapy monitoring and follow-up. Due to the high cancer risk in people with cancer predisposition syndromes (CPS), this blood-based and less invasive form of cancer detection is particularly promising for CPS patients.
All information about the project and all documents for participation can be found in the new “Liquid Biopsy” section of our website. A click on the button below will take you there directly.